Resumen

TABAKOV, A.; APARICIO HERNANDEZ, R.; PEREZ MORAN, M.J.  y  PRATS OLIVAN, P.. Possitive assesment of drugs: September, October and November 2014. Sanid. Mil. [online]. 2015, vol.71, n.1, pp.35-43. ISSN 1887-8571.  https://dx.doi.org/10.4321/S1887-85712015000100007.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2014, and considered of interest to the healthcare profesional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palabras clave : Afamelanotida; Scenesse^®; Apremilast; Aotezla^®; Balugrastim; Egranli^®; Darunavir/Cobicistat; Rezolsta^®; Dasabuvir Sódico; Exviera^®; Dulaglutida Trulicity^®; Eliglustat; Cerdelga^®; Estrógenos Conjugados/Bazedoxifeno; Duavive^®; Ketoconazol; Ketoconazol Hra Pharma^®; Naloxegol; Moventig^®; Nintedanib; Vargatef^®; Ofev^®; Nonacog Gamma; Rixubis^®; Olaparib; Lynparza^®; Ombitasvir/Paritaprevir/Ritonavir; Viekirax^®; Ospemifeno; Senshio^®; Ramucirumab; Cyramza^®; Secukinumab; Consentyx^®; Sofosbuvir/Ledipasvir; Harvoni^®; Tilmanocept; Lymphoseek^®; Vorapaxar; Zontivity^®.

        · resumen en Español     · texto en Español     · Español ( pdf )